Compounds for treating neurodegenerative proteinopathies
View Patent ↗This invention relates to compounds (e.g., those delineated herein), pharmaceutically acceptable salts, prodrugs, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering modulating compounds or compositions that modulate Aβ, PAMPS and DAMPS.
1. A fusion polypeptide comprising an isolated soluble Toll-Like Receptor 5 (sTLR5), or a fragment thereof comprising
a ligand binding site of the sTLR5, fused to an Fc polypeptide, and
a tag polypeptide, wherein
the tag polypeptide is a TAP polypeptide encoded by SEQ ID NO: 7.
2. The fusion polypeptide of claim 1 , wherein the sTLR5 polypeptide and the Fc polypeptide are connected by a peptide linker.
3. The fusion polypeptide of claim 2 , wherein the Fc polypeptide is an IgG1 polypeptide.
4. The fusion polypeptide of claim 3 , wherein the Fc polypeptide is encoded by SEQ ID NO: 8 or SEQ ID NO: 9.
5. The fusion polypeptide of claim 1 , wherein the C-terminus of the sTLR5 polypeptide is connected to the N-terminus of the Fc polypeptide.
6. The fusion polypeptide of claim 1 , wherein the sTLR5 or fragment thereof is encoded by SEQ ID NO: 3 or SEQ ID NO: 6.
7. A pharmaceutical composition comprising the fusion polypeptide of claim 1 .
8. The composition of claim 7 , further comprising an additional therapeutic agent.
9. A nucleic acid molecule encoding the fusion polypeptide of claim 1 .
10. A vector comprising the nucleic acid of claim 9 .
11. The vector of claim 10 , wherein the vector is an Adeno-associated viral vector (AAV), lentiviral vector, retroviral vector, or herpes simplex viral vector.